Affordable Access

deepdyve-link
Publisher Website

Proteasome Inhibitors as a Potential Cause of Heart Failure.

Authors
  • Koulaouzidis, Georgios1
  • Lyon, Alexander R2
  • 1 NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London SW3 6NP, UK.
  • 2 NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London SW3 6NP, UK; Imperial College London, London, UK. Electronic address: [email protected]
Type
Published Article
Journal
Heart failure clinics
Publication Date
Apr 01, 2017
Volume
13
Issue
2
Pages
289–295
Identifiers
DOI: 10.1016/j.hfc.2016.12.001
PMID: 28279415
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Proteasome inhibitors have become an important drug class in the treatment of multiple myeloma. In addition to its role in myeloma cells, the proteasome plays a critical role in the myocardium, particularly in the context of cardiac stress. The growing awareness of the cardiovascular toxicity of proteasome inhibitors is emerging following the phase 3 trials and the transition into real-world practice. This article reviews the background to this problem and the incidence of the problem in phase 3 trials and subsequent phase 2 trials in new patient cohorts and discusses the strategy to detect and manage this emerging problem. Copyright © 2016 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times